Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit.
Journal: Immunity
Published: August 07, 2025
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab.
Journal: Nature communications
Published: March 24, 2025
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Journal: Experimental dermatology
Published: March 25, 2015
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Journal: The Journal of allergy and clinical immunology
Published: November 21, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Journal: Journal of drugs in dermatology : JDD
Published: August 30, 2013
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Journal: Lancet (London, England)
Published: July 04, 2012
Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Journal: American journal of clinical dermatology
Published: May 17, 2012
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Journal: The New England journal of medicine
Published: March 30, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026